Cancer Chemoprevention: Current State of the Art

被引:57
|
作者
Landis-Piwowar, Kristin R. [1 ]
Iyer, Neena R. [1 ]
机构
[1] Oakland Univ, Sch Hlth Sci, Biomed Diagnost & Therapeut Sci, Rochester, MI 48063 USA
来源
关键词
blocking agents; chemoprevention; phytochemicals; suppressing agents;
D O I
10.4137/CGM.S11288
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The aim of cancer chemoprevention is disruption or delay of the molecular pathways that lead to carcinogenesis. Chemopreventive blocking and/or suppressing agents disrupt the molecular mechanisms that drive carcinogenesis such as DNA damage by reactive oxygen species, increased signal transduction to NF-kB, epigenomic deregulation, and the epithelial mesenchymal transition that leads to metastatic progression. Numerous dietary phytochemicals have been observed to inhibit the initiation phase of carcinogenesis, and therefore are useful in primary chemoprevention. Moreover, phytochemicals are capable of interfering with the molecular mechanisms of metastasis. Likewise, numerous synthetic compounds are relevant and clinically viable as chemopreventive agents during the fundamental stages of carcinogenesis. While molecularly targeted anti- cancer therapies are in constant stages of development, superior patient outcomes are observed if carcinogenic processes are prevented altogether. This article reviews the role of chemopreventive compounds in inhibition of cancer initiation and their ability to reduce cancer progression.
引用
收藏
页码:19 / 25
页数:7
相关论文
共 50 条
  • [41] Current State of the Art
    Goss, Glenwood
    Spaans, Johanna
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S79 - S80
  • [42] State of the art in imaging and chemoprevention for high-risk patients
    Hofstatter E.W.
    Andrejeva L.
    Chagpar A.B.
    [J]. Current Breast Cancer Reports, 2013, 5 (2) : 125 - 133
  • [43] Neoadjuvant immune checkpoint inhibitors in cancer, current state of the art
    Le Saux, Olivia
    Lounici, Yasmine
    Wajda, Pauline
    Barrin, Sarah
    Caux, Christophe
    Dubois, Bertrand
    Ray-Coquard, Isabelle
    [J]. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2021, 157
  • [44] Management of small cell lung cancer: Current state of the art
    Johnson, DH
    [J]. CHEST, 1999, 116 (06) : 525S - 530S
  • [45] Triple-negative breast cancer: current state of the art
    Rastelli, Francesca
    Biancanelli, Sandra
    Falzetta, Amalia
    Martignetti, Angelo
    Casi, Camilla
    Bascioni, Romeo
    Giustini, Lucio
    Crispino, Sergio
    [J]. TUMORI JOURNAL, 2010, 96 (06): : 875 - 888
  • [46] Polygenic susceptibility to breast cancer: current state-of-the-art
    Ghoussaini, Maya
    Pharoah, Paul D. P.
    [J]. FUTURE ONCOLOGY, 2009, 5 (05) : 689 - 701
  • [47] Molecular pathology of breast cancer Challenges and current state of the art
    Lebeau, Annette
    [J]. GYNAKOLOGE, 2020, 53 (05): : 284 - 291
  • [48] Imaging of Precision Therapy for Lung Cancer: Current State of the Art
    Park, Hyesun
    Sholl, Lynette M.
    Hatabu, Hiroto
    Awad, Mark M.
    Nishino, Mizuki
    [J]. RADIOLOGY, 2019, 293 (01) : 15 - 29
  • [49] Nanomedicine applications in the treatment of breast cancer: current state of the art
    Wu, Di
    Si, Mengjie
    Xue, Hui-Yi
    Wong, Ho-Lun
    [J]. INTERNATIONAL JOURNAL OF NANOMEDICINE, 2017, 12 : 5879 - 5892
  • [50] Chemoprevention of prostate cancer: Current status and future directions
    Lieberman, R
    [J]. CANCER AND METASTASIS REVIEWS, 2002, 21 (3-4) : 297 - 309